Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Vanda’s social anxiety drug flunks Phase 3 trial in female patients

Vanda Pharmaceuticals said Wednesday it is putting its social anxiety disorder program on hold following a late-stage trial failure. The biotech’s drug, called VQW-765, missed the primary endpoint in a Phase ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 15 October →